Defibrotide Inhibits Platelet Activation by Cathepsin G Released From Stimulated Polymorphonuclear Leukocytes

Summary

Defibrotide is a polydeoxyribonucleotide with antithrombotic effects in experimental animal models. Most of the actions of this drug have been observed in in vivo test models but no effects have been reported in in vitro systems. In this paper we demonstrate that defibrotide interferes with polymorphonuclear leukocyte-induced human platelet activation in vitro. This effect was not related to any direct interaction with polymorphonuclear leukocytes or platelets, but was due to the inhibition of cathepsin G, the main biochemical mediator of this cell-cell cooperation. Since cathepsin G not only induces platelet activation but also affects some endothelial cell functions, the anticathepsin G activity of defibrotide could help to explain the antithrombotic effect of this drug.

• References

• 1 Fareed J, Walenga JM, Hoppensteadt DA, Kumar A, Ulutin ON, Cornelli U. Pharmacologic profiling of defibrotide in experimental models. Semin Thromb Haemostas 1988; Suppl (14) 27-37
• 2 Thiemermann C, Thomas GR, Vane JR. Defibrotide reduces infarct size in a rabbit model of experimental myocardial ischemia and reperfusion. Br J Pharmacol 1989; 97: 401-408
• 3 Fumagalli G, Angelaccio E, Lombardo N, Clementi F. Morphometric and ultrastructural study of experimental venous thrombosis. Haemostasis 1987; 17: 361-370
• 4 Di Perri T, Laghi Pasini F, Capacchi PL, Ceccatelli L, Pasqui AL, Orrico A. Defibrotide in vitro inhibits neutrophil activation by a Ca⁺⁺-involving mechanism. Int J Tissue Reac 1987; 9: 399-406
• 5 Ernst E, Hammerschmidt DE, Bagge U, Matrai A, Dormandy JA. Leukocytes and the risk of ischemic diseases. JAMA 1987; 257: 2318-2324
• 6 Nash GB, Thomas PRS, Dormandy JM. Abnormal flow properties of white cells in patients with severe ischemia of the leg. Br Med J 1988; 296: 1699-1701
• 7 Mehta J, Dinerman J, Mehta P, Saldeen TPG, Lawson D, Donnelly WH, Wallin R. Neutrophil function in ischemic heart disease. Circulation 1989; 79: 549-556
• 8 Thomas PRS, Nash GB, Dormandy JA. White cell accumulation in dependent legs of patients with venous hypertension: a possible mechanism for trophic changes in the skin. Br Med J 1988; 296: 1693-1695
• 9 Chignard M, Selak MA, Smith JB. Direct evidence for the existence of a neutrophil-derived platelet activator (neutrophilin). Proc Natl Acad Sci USA 1986; 83: 8609-8613
• 10 Del Maschio A, Evangelista V, Rajtar G, Chen ZM, Cerletti C, de Gaetano G. Platelet activation by polymorphonuclear leukocytes exposed to chemotactic agents. Am J Physiol 1990; 258: H870-9
• 11 Selak MA, Chignard M, Smith JB. Cathepsin G is a strong platelet agonist released by neutrophils. Biochem J 1988; 251: 293-299
• 12 Evangelista V, Rajtar G, de Gaetano G, White JG, Cerletti C. Platelet activation by fMLP-stimulated polymorphonuclear leukocytes: the activity of cathepsin G is not prevented by antiproteinases. Blood 1991; 77: 2379-2388
• 13 Boyum A. A one stage procedure for isolation of granulocytes from human blood. General sedimentation properties of white blood cells in a 1 g gravity field. Scand J Clin Lab Invest 1968; Suppl (97) 51-76
• 14 Nakajima K, Powers JC, Ashe BM, Zimmerman M. Mapping the extended substrate binding site of cathepsin G and human leukocyte elastase. Studies with peptide substrate related to the di-protease inhibitor reactive site. J Biol Chem 1979; 254: 4027-4032
• 15 Buczko W, Invernizzi R, de Gaetano G. High pressure liquid chromatography microassay for platelet serotonin. Thromb Haemo-stas 1984; 51: 131
• 16 Selak MA, Smith JB. Cathepsin G binding to human platelets. Evidence for a specific receptor. Biochem J 1990; 266: 55-62
• 17 Redini F, Tixier JM, Petitou M, Choay J, Robert L, Hornebeck W. Inhibition of leukocytes elastase by heparin and its derivatives. Biochem J 1988; 252: 515-519
• 18 Evangelista V, Rajtar G, Piccardoni P, de Gaetano G, White JG, Cerletti C. Platelet activation by PMN-derived cathepsin G: effects of antiproteinases and heparin. Thromb Haemostas 1991; 65: 1976A
• 19 Cornelli U, Nazzari M. Defibrotide: an overview of clinical pharmacology and early clinical studies. Semin Thromb Hemostas 1988; Suppl (14) 64-70
• 20 Ciuffetti G, Balendra R, Lennie SE, Anderson J, Lowe GDO. Impaired filterability of white cells in acute cerebral infarction. Br Med J 1989; 298: 930-931
• 21 Violi F, Ferro D, Alessandri C, Quintarelli C, Saliola M, Balsano F. Inhibition of tissue plasminogen activator inhibitor by defibrotide in atherosclerotic patients. Semin Thromb Hemostas 1989; Suppl (15) 226-229
• 22 Costantini V, Luzi P, Boselli C, Bastiano ML, Bisacci R, Nenci GG. Effects of defibrotide on prostanoid synthesis and fibrinolytic activity in human veins. Eur J Int Med 1989; 1: 115-120
• 23 Weksler BB, Jaffe EA, Brower MS, Cole OF. Human leukocyte cathepsin G and elastase specifically suppress thrombin-induced prostacyclin production in human endothelial cells. Blood 1989; 74: 1627-1634
• 24 Pintucci G, Iacoviello L, Amore C, Evangelista V, Cerletti C, Donati MB. Cathepsin G-induced release of PAI-1 from platelets and endothelial cells: a new thrombogenic property of PMN?. Blood 1991; 78: 397a